ENTO
Entero Therapeutics Inc
$
4.000
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.190
Open
4.100
VWAP
4.03
Vol
123.81K
Mkt Cap
8.05M
Low
3.950
Amount
498.90K
EV/EBITDA(TTM)
--
Total Shares
2.01M
EV
70.67M
EV/OCF(TTM)
--
P/S(TTM)
--
Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The Company is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The Company is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
Show More
Valuation Metrics
The current forward P/E ratio for Entero Therapeutics Inc (ENTO.O) is -0.88, compared to its 5-year average forward P/E of -3.43. For a more detailed relative valuation and DCF analysis to assess Entero Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.43
Current PE
-0.88
Overvalued PE
6.01
Undervalued PE
-12.87
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.08
Current PS
0.00
Overvalued PS
0.44
Undervalued PS
-0.28
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
-81.35%
-638.86K
Operating Profit
FY2025Q2
YoY :
-91.22%
-674.93K
Net Income after Tax
FY2025Q2
YoY :
-94.04%
-0.23
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 119.34% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
465.0
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 119.34% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
465.0
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ENTO News & Events
Events Timeline
2025-05-12 (ET)
2025-05-12
16:23:27
Entero Therapeutics files to sell 16.67M shares of common stock
2025-03-13 (ET)
2025-03-13
08:35:05
Vicarious Surgical appoints Sarah Romano as CFO
2025-02-14 (ET)
2025-02-14
16:01:10
Entero Therapeutics names Richard Paolone as interim CEO
Sign Up For More Events
Sign Up For More Events
News
2.0
08-28BenzingaFive Biotech Stocks Showing Significant Momentum
9.0
08-17TipRanksUpcoming Stock Splits This Week (August 18 to August 22) – Stay Invested
2.0
08-12TipRanks3 Penny Stocks to Watch Now, 8/12/25
Sign Up For More News
People Also Watch
FAQ
What is Entero Therapeutics Inc (ENTO) stock price today?
The current price of ENTO is 4 USD — it has decreased -2.91 % in the last trading day.
What is Entero Therapeutics Inc (ENTO)'s business?
What is the price predicton of ENTO Stock?
What is Entero Therapeutics Inc (ENTO)'s revenue for the last quarter?
What is Entero Therapeutics Inc (ENTO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Entero Therapeutics Inc (ENTO)'s fundamentals?
How many employees does Entero Therapeutics Inc (ENTO). have?